Abstract

Arasin 1 is a 37 amino acid long proline-rich antimicrobial peptide isolated from the spider crab, Hyas araneus. In this work the active region of arasin 1 was identified through structure-activity studies using different peptide fragments derived from the arasin 1 sequence. The pharmacophore was found to be located in the proline/arginine-rich NH2 terminus of the peptide and the fragment arasin 1(1–23) was almost equally active to the full length peptide. Arasin 1 and its active fragment arasin 1(1–23) were shown to be non-toxic to human red blood cells and arasin 1(1–23) was able to bind chitin, a component of fungal cell walls and the crustacean shell. The mode of action of the fully active N-terminal arasin 1(1–23) was explored through killing kinetic and membrane permeabilization studies. At the minimal inhibitory concentration (MIC), arasin 1(1–23) was not bactericidal and had no membrane disruptive effect. In contrast, at concentrations of 5×MIC and above it was bactericidal and interfered with membrane integrity. We conclude that arasin 1(1–23) has a different mode of action than lytic peptides, like cecropin P1. Thus, we suggest a dual mode of action for arasin 1(1–23) involving membrane disruption at peptide concentrations above MIC, and an alternative mechanism of action, possibly involving intracellular targets, at MIC.

Highlights

  • Since the widespread resistance of bacterial pathogens against conventional antibiotics often makes antibiotic treatment inefficient, medical treatment of bacterial infections is today no longer a simple matter of prescribing antibiotic therapy

  • To address which part of arasin 1 is responsible for the antimicrobial activity, a series of truncated arasin 1 peptides were synthesized (Fig. 1), and their antimicrobial activity was determined and compared to arasin 1

  • Arasin 1 which is a PR-Antimicrobial peptides (AMPs) [27], was active against the whole panel of test strains used in this study (Table 1)

Read more

Summary

Introduction

Since the widespread resistance of bacterial pathogens against conventional antibiotics often makes antibiotic treatment inefficient, medical treatment of bacterial infections is today no longer a simple matter of prescribing antibiotic therapy. The interest in novel natural products with antimicrobial activity, as substitutes for the conventional antibiotics and new drug leads, is steadily increasing. Antimicrobial peptides (AMPs) are cationic and amphipathic molecules widely distributed amongst organisms of probably all taxonomic phyla and act as innate antibiotics. They are constitutively produced or synthesized after infection or injury, and exhibit desirable antimicrobial properties such as a rapid action and a broad activity spectrum [1,2]. Substantial research remains in exploring these molecules’ mechanism of action, and creating stable and easier-to-produce peptide analogs for medical applications

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call